BR9912524A - Compostos macrocìclicos antivirais - Google Patents
Compostos macrocìclicos antiviraisInfo
- Publication number
- BR9912524A BR9912524A BR9912524-2A BR9912524A BR9912524A BR 9912524 A BR9912524 A BR 9912524A BR 9912524 A BR9912524 A BR 9912524A BR 9912524 A BR9912524 A BR 9912524A
- Authority
- BR
- Brazil
- Prior art keywords
- viral
- compounds
- relates
- macrocyclic compounds
- present
- Prior art date
Links
- 230000000840 anti-viral effect Effects 0.000 title abstract 3
- 150000002678 macrocyclic compounds Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 102000009410 Chemokine receptor Human genes 0.000 abstract 1
- 108050000299 Chemokine receptor Proteins 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 230000004071 biological effect Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000013020 embryo development Effects 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 125000002950 monocyclic group Chemical group 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229920000768 polyamine Polymers 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
- C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
- C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
- C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
- C04B35/632—Organic additives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/06—Peri-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Ceramic Engineering (AREA)
- Manufacturing & Machinery (AREA)
- Virology (AREA)
- Structural Engineering (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Oncology (AREA)
- Materials Engineering (AREA)
- Communicable Diseases (AREA)
- Inorganic Chemistry (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/111,895 US6506770B1 (en) | 1996-06-06 | 1998-07-08 | Antiviral compounds |
| PCT/CA1999/000619 WO2000002870A1 (en) | 1998-07-08 | 1999-07-08 | Antiviral macrocyclic compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR9912524A true BR9912524A (pt) | 2001-05-02 |
Family
ID=22341015
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR9912524-2A BR9912524A (pt) | 1998-07-08 | 1999-07-08 | Compostos macrocìclicos antivirais |
Country Status (17)
| Country | Link |
|---|---|
| US (6) | US6506770B1 (enExample) |
| EP (1) | EP1095031B1 (enExample) |
| JP (1) | JP4637353B2 (enExample) |
| KR (1) | KR100778134B1 (enExample) |
| CN (2) | CN100339080C (enExample) |
| AP (1) | AP1436A (enExample) |
| AU (1) | AU767359B2 (enExample) |
| BR (1) | BR9912524A (enExample) |
| CA (1) | CA2336634C (enExample) |
| HU (1) | HUP0102930A3 (enExample) |
| IL (1) | IL140605A0 (enExample) |
| MX (1) | MXPA01000137A (enExample) |
| NO (1) | NO20010047L (enExample) |
| NZ (1) | NZ509699A (enExample) |
| PL (1) | PL345516A1 (enExample) |
| TR (1) | TR200100030T2 (enExample) |
| WO (1) | WO2000002870A1 (enExample) |
Families Citing this family (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6506770B1 (en) | 1996-06-06 | 2003-01-14 | Anormed, Inc. | Antiviral compounds |
| GB9511357D0 (en) * | 1995-06-06 | 1995-08-02 | Johnson Matthey Plc | Improved antiviral compounds |
| US20050085555A1 (en) * | 1997-08-21 | 2005-04-21 | Murphy Michael A. | Composition, synthesis and therapeutic applications of polyamines |
| US6365583B1 (en) | 1999-02-02 | 2002-04-02 | Anormed, Inc. | Methods to enhance white blood cell count |
| HK1046409A1 (zh) * | 1999-12-17 | 2003-01-10 | Anormed Inc. | 结合趋化因子受体的杂环化合物 |
| AU9355101A (en) * | 2000-09-15 | 2002-03-26 | Anormed Inc | Chemokine receptor binding heterocyclic compounds |
| RU2277092C2 (ru) * | 2000-09-15 | 2006-05-27 | Анормед, Инк. | Гетероциклические соединения, их применение и фармацевтическая композиция для лечения состояний, опосредованных схсr4 и ccr5 |
| US7052676B2 (en) * | 2000-09-26 | 2006-05-30 | The Regents Of The University Of Michigan | Methods for inhibition of HIV replication using a small molecule inhibitor |
| US6987102B2 (en) * | 2001-07-31 | 2006-01-17 | Anormed, Inc. | Methods to mobilize progenitor/stem cells |
| US7169750B2 (en) * | 2001-07-31 | 2007-01-30 | Anormed, Inc. | Methods to mobilize progenitor/stem cells |
| US7354932B2 (en) | 2001-12-21 | 2008-04-08 | Anormed, Inc. | Chemokine receptor binding heterocyclic compounds with enhanced efficacy |
| RU2325387C2 (ru) * | 2001-12-21 | 2008-05-27 | Анормед Инк. | Гетероциклические соединения с повышенной эффективностью, связывающиеся с рецептором хемокина |
| US20030199464A1 (en) * | 2002-04-23 | 2003-10-23 | Silviu Itescu | Regeneration of endogenous myocardial tissue by induction of neovascularization |
| US7504422B2 (en) | 2003-04-02 | 2009-03-17 | Taigen Biotechnology Co. Ltd. | Polyamine compounds |
| CA2521416A1 (en) | 2003-04-02 | 2004-10-21 | Taigen Biotechnology | Polyamine compounds for treating chemokine receptor mediated diseases |
| CA2520259A1 (en) | 2003-04-11 | 2004-10-28 | Anormed Inc. | Cxcr4 chemokine receptor binding compounds |
| CA2517077C (en) | 2003-04-22 | 2013-03-12 | Anormed Inc. | Chemokine receptor binding heterocyclic compounds with enhanced efficacy |
| US7501518B2 (en) | 2003-04-22 | 2009-03-10 | Genzyme Corporation | Methods of making 2,6-diaryl piperidine derivatives |
| JPWO2005051927A1 (ja) * | 2003-11-26 | 2007-12-06 | 株式会社クレハ | Ｈｉｖ−１感染末梢血単核球の刺激培養によるｃｄ４陽性ｔ細胞の培養方法、及びｈｉｖ−１の増殖阻害剤 |
| CA2577046A1 (en) * | 2004-08-13 | 2006-02-23 | Anormed Inc. | Chemokine combinations to mobilize progenitor/stem cells |
| US7501526B2 (en) | 2005-01-20 | 2009-03-10 | Taigen Biotechnology | Synthesis of polyamine compounds |
| US7825088B2 (en) * | 2005-04-25 | 2010-11-02 | The Cbr Institute For Biomedical Research, Inc. | Methods for the treatment of multiple myeloma |
| US8569280B2 (en) * | 2005-04-25 | 2013-10-29 | Immune Disease Institute | Methods for the treatment of multiple myeloma |
| CN101365336B (zh) * | 2005-08-19 | 2013-05-29 | 健赞股份有限公司 | 增强化疗的方法 |
| US20090035318A1 (en) * | 2005-09-29 | 2009-02-05 | British Columbia Cancer Agency Branch | Method and composition for increasing the engraftment efficiency of stem cells |
| EP2397148A3 (en) | 2006-02-02 | 2012-04-25 | Allergan, Inc. | Compositions and methods for the treatment of ophthalmic disease |
| RU2420284C2 (ru) * | 2006-06-12 | 2011-06-10 | Пфайзер Продактс Инк. | Антагонист ccr5 для усиления иммуновосстановительной терапии и лечения оппортунистической инфекции у пациентов с вич |
| AR063470A1 (es) * | 2006-08-02 | 2009-01-28 | Genzyme Corp | Terapia combinada |
| US20100178271A1 (en) * | 2006-08-07 | 2010-07-15 | Genzyme Corporation | Combination Therapy |
| US20090274687A1 (en) * | 2008-05-02 | 2009-11-05 | University Of Miami | Attenuation of hypoxia induced cardiovascular disorders |
| US20110281814A1 (en) * | 2009-01-30 | 2011-11-17 | Genzyme Corporation | Methods and compositions for treating breast cancer |
| WO2010126888A1 (en) * | 2009-05-01 | 2010-11-04 | Glycomimetics, Inc. | Heterobifunctional inhibitors of e-selectins and cxcr4 chemokine receptors |
| US8921328B2 (en) | 2010-09-14 | 2014-12-30 | Glycomimetics, Inc. | E-selectin antagonists |
| GB201017345D0 (en) | 2010-10-14 | 2010-11-24 | Proximagen Ltd | Receptor antagonists |
| WO2012061662A1 (en) * | 2010-11-03 | 2012-05-10 | Glycomimetics, Inc. | Glycomimetic-peptidomimetic inhibitors of e-selectins and cxcr4 chemokine receptors |
| KR20200016407A (ko) | 2011-05-16 | 2020-02-14 | 젠자임 코포레이션 | Ｃｘｃｒ４ 길항제의 용도 |
| CN103159690B (zh) * | 2011-12-14 | 2015-03-25 | 朱靖华 | 对称大环胺化合物的结晶形式 |
| ES2655443T7 (es) | 2011-12-22 | 2021-03-22 | Glycomimetics Inc | Compuestos antagonistas de E-selectina |
| LT2928476T (lt) | 2012-12-07 | 2018-05-25 | Glycomimetics, Inc. | Junginiai, kompozicijos ir būdai, naudojant e-selektino antagonistus, hemopoetinių ląstelių mobilizacijai |
| CN103058998B (zh) * | 2013-01-16 | 2016-04-13 | 山东鲁北药业有限公司 | 一种amd3465的制备工艺 |
| ES2754549T3 (es) | 2014-12-03 | 2020-04-20 | Glycomimetics Inc | Inhibidores heterobifuncionales de E-selectinas y receptores de quimioquinas CXCR4 |
| PL3277284T3 (pl) * | 2015-04-02 | 2021-03-08 | Proximagen, Llc | Nowe terapie nowotworu |
| WO2017011517A1 (en) | 2015-07-16 | 2017-01-19 | Emory University | Bis-amines, compositions, and uses related to cxcr4 inhibition |
| CA3000844A1 (en) * | 2015-10-19 | 2017-04-27 | Ramot At Tel-Aviv University Ltd. | Methods and compositions for treating neurodegenerative diseases |
| WO2017106332A1 (en) | 2015-12-14 | 2017-06-22 | X4 Pharmaceuticals, Inc. | Methods for treating cancer |
| JP6864296B2 (ja) | 2015-12-14 | 2021-04-28 | エックス４ ファーマシューティカルズ， インコーポレイテッド | がんを処置する方法 |
| PL3393468T3 (pl) | 2015-12-22 | 2023-01-23 | X4 Pharmaceuticals, Inc. | Metody leczenia niedoboru odporności |
| WO2017151708A1 (en) | 2016-03-02 | 2017-09-08 | Glycomimetics, Inc. | Methods for the treatment and/or prevention of cardiovescular disease by inhibition of e-selectin |
| CA3019394A1 (en) | 2016-04-08 | 2017-10-12 | X4 Pharmaceuticals, Inc. | Methods for treating cancer |
| US11433048B2 (en) | 2016-06-16 | 2022-09-06 | Centre National De La Recherche Scientifique | CXCR4 receptor-binding compounds useful for increasing interferon level |
| ES2870920T3 (es) | 2016-06-21 | 2021-10-28 | X4 Pharmaceuticals Inc | Inhibidores de CXCR4 y usos de los mismos |
| JP7084624B2 (ja) | 2016-06-21 | 2022-06-15 | エックス４ ファーマシューティカルズ， インコーポレイテッド | Ｃｘｃｒ４阻害剤およびその使用 |
| JP6994767B2 (ja) | 2016-06-21 | 2022-01-14 | エックス４ ファーマシューティカルズ， インコーポレイテッド | Ｃｘｃｒ４阻害剤およびその使用 |
| WO2018031445A1 (en) | 2016-08-08 | 2018-02-15 | Glycomimetics, Inc. | Combination of t-cell checkpoint inhibitors with inhibitors of e-selectin or cxcr4, or with heterobifunctional inhibitors of both e-selectin and cxcr4 |
| KR20240046288A (ko) | 2016-10-07 | 2024-04-08 | 글리코미메틱스, 인크. | 매우 강력한 다량체성 e-셀렉틴 길항물질 |
| US11197877B2 (en) | 2017-03-15 | 2021-12-14 | Glycomimetics. Inc. | Galactopyranosyl-cyclohexyl derivauves as E-selectin antagonists |
| US20190343885A1 (en) | 2017-10-31 | 2019-11-14 | Magenta Therapeutics Inc. | Compositions and methods for hematopoietic stem and progenitor cell transplant therapy |
| CN111542597A (zh) | 2017-10-31 | 2020-08-14 | 美真达治疗公司 | 用于扩增造血干细胞和祖细胞的组合物和方法 |
| US11712446B2 (en) | 2017-11-30 | 2023-08-01 | Glycomimetics, Inc. | Methods of mobilizing marrow infiltrating lymphocytes and uses thereof |
| US11260079B2 (en) | 2017-12-06 | 2022-03-01 | Magenta Therapeutics, Inc. | Dosing regimens for the mobilization of hematopoietic stem and progenitor cells |
| US10058573B1 (en) | 2017-12-06 | 2018-08-28 | Magenta Therapeutics, Inc. | Dosing regimens for the mobilization of hematopoietic stem cells |
| AU2018378804B2 (en) | 2017-12-06 | 2025-10-02 | Ensoma, Inc. | Dosing regimens for the mobilization of hematopoietic stem and progenitor cells |
| CN109988153B (zh) * | 2017-12-29 | 2021-11-19 | 深圳夏浠湾医药科技有限公司 | 一种川芎嗪衍生物及其制备方法和应用 |
| US11548908B2 (en) | 2017-12-29 | 2023-01-10 | Glycomimetics, Inc. | Heterobifunctional inhibitors of E-selectin and galectin-3 |
| WO2019136159A1 (en) | 2018-01-03 | 2019-07-11 | Magenta Therapeutics Inc. | Compositions and methods for the expansion of hematopoietic stem and progenitor cells and treatment of inherited metabolic disorders |
| BR112020018184A2 (pt) | 2018-03-05 | 2021-02-02 | Glycomimetics, Inc. | usos de compostos |
| US10548889B1 (en) | 2018-08-31 | 2020-02-04 | X4 Pharmaceuticals, Inc. | Compositions of CXCR4 inhibitors and methods of preparation and use |
| US11845771B2 (en) | 2018-12-27 | 2023-12-19 | Glycomimetics, Inc. | Heterobifunctional inhibitors of E-selectin and galectin-3 |
| WO2021087406A1 (en) | 2019-11-01 | 2021-05-06 | Magenta Therapeutics, Inc. | Dosing regimens for the mobilization of hematopoietic stem and progentor cells |
| CA3171250A1 (en) | 2020-03-10 | 2021-09-16 | E. Lynne KELLEY | Methods for treating neutropenia |
| IL297690A (en) | 2020-04-27 | 2022-12-01 | Magenta Therapeutics Inc | Methods and compositions for transducing hematopoietic stem and progenitor cells in vivo |
| EP4308694A1 (en) | 2021-03-16 | 2024-01-24 | Magenta Therapeutics, Inc. | Dosing regimens for hematopoietic stem cell mobilization for stem cell transplants in multiple myeloma patients |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5021409A (en) | 1989-12-21 | 1991-06-04 | Johnson Matthey Plc | Antiviral cyclic polyamines |
| GB9105489D0 (en) | 1991-03-15 | 1991-05-01 | Johnson Matthey Plc | Improvements in chemical compounds |
| GB9126677D0 (en) | 1991-12-16 | 1992-02-12 | Johnson Matthey Plc | Improvements in chemical compounds |
| GB9400411D0 (en) | 1994-01-11 | 1994-03-09 | Johnson Matthey Plc | Improvements in chemical compounds |
| GB9511357D0 (en) | 1995-06-06 | 1995-08-02 | Johnson Matthey Plc | Improved antiviral compounds |
| US6506770B1 (en) | 1996-06-06 | 2003-01-14 | Anormed, Inc. | Antiviral compounds |
| DE69914463T2 (de) | 1998-03-13 | 2004-11-11 | The University Of British Columbia, Vancouver | Therapeutische chemokine rezeptor antagonisten |
| WO2000009152A1 (en) | 1998-08-14 | 2000-02-24 | The University Of British Columbia | Therapeutic chemokine receptor antagonists |
| EP1745797A3 (en) * | 1998-03-24 | 2007-07-18 | Chugai Seiyaku Kabushiki Kaisha | Vascularization inhibitors |
| WO1999065507A1 (en) | 1998-06-19 | 1999-12-23 | The General Hospital Corporation | Modulating platelet function |
| WO2000006086A2 (en) * | 1998-07-31 | 2000-02-10 | The Trustees Of Columbia University In The City Of New York | Use of inhibitors of the activation of cxcr4 receptor by sdf-1 in treating rheumatoid arthritis |
| US6365583B1 (en) | 1999-02-02 | 2002-04-02 | Anormed, Inc. | Methods to enhance white blood cell count |
| WO2005002522A2 (en) | 2003-06-30 | 2005-01-13 | Caritas St. Elizabeth's Medical Center Of Boston, Inc. | Compositions and methods for treating tissue ischemia |
| US7315917B2 (en) * | 2005-01-20 | 2008-01-01 | Sandisk Corporation | Scheduling of housekeeping operations in flash memory systems |
-
1998
- 1998-07-08 US US09/111,895 patent/US6506770B1/en not_active Expired - Lifetime
-
1999
- 1999-07-08 MX MXPA01000137A patent/MXPA01000137A/es active IP Right Grant
- 1999-07-08 BR BR9912524-2A patent/BR9912524A/pt not_active Application Discontinuation
- 1999-07-08 CN CNB2005100094866A patent/CN100339080C/zh not_active Expired - Lifetime
- 1999-07-08 CN CNB998082600A patent/CN1195745C/zh not_active Expired - Fee Related
- 1999-07-08 WO PCT/CA1999/000619 patent/WO2000002870A1/en not_active Ceased
- 1999-07-08 AP APAP/P/2001/002043A patent/AP1436A/en active
- 1999-07-08 EP EP99928956.4A patent/EP1095031B1/en not_active Expired - Lifetime
- 1999-07-08 US US09/743,561 patent/US6872714B1/en not_active Expired - Lifetime
- 1999-07-08 NZ NZ509699A patent/NZ509699A/en not_active IP Right Cessation
- 1999-07-08 IL IL14060599A patent/IL140605A0/xx unknown
- 1999-07-08 KR KR1020017000220A patent/KR100778134B1/ko not_active Expired - Fee Related
- 1999-07-08 CA CA002336634A patent/CA2336634C/en not_active Expired - Fee Related
- 1999-07-08 AU AU45959/99A patent/AU767359B2/en not_active Expired
- 1999-07-08 TR TR2001/00030T patent/TR200100030T2/xx unknown
- 1999-07-08 HU HU0102930A patent/HUP0102930A3/hu unknown
- 1999-07-08 PL PL99345516A patent/PL345516A1/xx not_active Application Discontinuation
- 1999-07-08 JP JP2000559101A patent/JP4637353B2/ja not_active Expired - Lifetime
-
2001
- 2001-01-04 NO NO20010047A patent/NO20010047L/no not_active Application Discontinuation
-
2002
- 2002-05-09 US US10/143,692 patent/US6756391B2/en not_active Expired - Lifetime
-
2004
- 2004-06-21 US US10/872,735 patent/US7160872B2/en not_active Expired - Fee Related
- 2004-11-17 US US10/991,944 patent/US7414065B2/en not_active Expired - Fee Related
-
2008
- 2008-07-29 US US12/182,044 patent/US7709486B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR9912524A (pt) | Compostos macrocìclicos antivirais | |
| Markowitz et al. | Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals | |
| Gray et al. | The NRTIs lamivudine, stavudine and zidovudine have reduced HIV-1 inhibitory activity in astrocytes | |
| Bicart-Sée et al. | Successful treatment with nitazoxanide of Enterocytozoon bieneusi microsporidiosis in a patient with AIDS | |
| Dutschman et al. | Novel 4′-substituted stavudine analog with improved anti-human immunodeficiency virus activity and decreased cytotoxicity | |
| DE50214416D1 (de) | Vermehrung von viren in zellkultur | |
| ES2109554T3 (es) | Agentes de reversion de la resistencia a multiples farmacos. | |
| BR0112703A (pt) | Processo para proteger motores de combustão interna compreendendo magnésio ou ligas de magnésio contra corrosão, e, uso de um concentrado anticongelante | |
| WO2005024422A3 (en) | Methods for identifying inhibitors | |
| Cihlar et al. | Novel nucleotide human immunodeficiency virus reverse transcriptase inhibitor GS-9148 with a low nephrotoxic potential: characterization of renal transport and accumulation | |
| CY1107787T1 (el) | Μεθοδοι και συνθεσεις για τον ελεγχο της κοκκιδιωσεως | |
| BR0215392A (pt) | Composições farmacêuticas compreendendo um inibidor de fosfodiesterase multifuncional e um inibidor de absorção de adenosina, bem como uso das mesmas | |
| BRPI0407299A (pt) | Métodos para detectar um analito associado com o hiv, para determinar a relação de células t cd4+ para células t cd8+, e para detectar rna do hiv, em uma amostra de sangue | |
| Qi et al. | Impact of nucleos (t) ide analogues on the estimated glomerular filtration rate in patients with chronic hepatitis B: a prospective cohort study in C hina | |
| BR0310077A (pt) | Novos compostos e sua utilização | |
| ATE428706T1 (de) | Chemokinrezeptor-bindende heterocyclische verbindungen | |
| TR200003470T2 (tr) | Ecteinascidin 743 Metabolitleri | |
| Fontaine | Metformin and respiratory chain complex I: the last piece of the puzzle? | |
| Sun et al. | Zidovudine induces downregulation of mitochondrial deoxynucleoside kinases: implications for mitochondrial toxicity of antiviral nucleoside analogs | |
| Bakowski et al. | Oral drug repositioning candidates and synergistic remdesivir combinations for the prophylaxis and treatment of COVID-19 | |
| BRPI0406100A (pt) | álcoois terciários insaturados como ligantes para catalisadores dmc | |
| CY1110285T1 (el) | Συζευγματα πολυαμινων με οξινα ρετινοειδη και παρασκευες τους | |
| Borroto-Esoda et al. | In vitro combination of amdoxovir and the inosine monophosphate dehydrogenase inhibitors mycophenolic acid and ribavirin demonstrates potent activity against wild-type and drug-resistant variants of human immunodeficiency virus type 1 | |
| Veler et al. | Guanylate-binding protein 5 antagonizes viral glycoproteins independently of furin processing | |
| Uckun et al. | In vivo toxicity, pharmacokinetics, and anti-human immunodeficiency virus activity of stavudine-5′-(p-bromophenyl methoxyalaninyl phosphate)(stampidine) in mice |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B15K | Others concerning applications: alteration of classification |
Free format text: ALTERADA DA INT.CL: C07D 257/02, C07D 401/12, C07D 409/12, C07D 403/12, C07D 471/06, C07D 471/08, C07D 401/06, C07D 473/00, A61K 31/395, A61K 31/4178, A61K 31/4353, A61K 31/44, A61K 31/4427, A61P 19/02, A61P 25/00, A61P 31/18, A61P 35/00, A61P 43/00 Ipc: C07D 257/02 (2009.01), C07D 401/12 (2009.01), C07D |
|
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O E 13 DA LPI |
|
| B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL. |